HCPCS code J1675: Histrelin acetate billing and reimbursement guide

Key takeaways

HCPCS code J1675 covers an injection of histrelin acetate at 10 micrograms. It is a Level II J-code for a GnRH agonist given in an office or outpatient setting.

Medicare Part B covers J1675 when a physician or qualified provider administers the injection. Self-administered formulations are excluded under CMS Article A53066.

In the office setting Medicare pays the drug and the administration code as two separate line items, not as one bundled payment.

Reimbursement follows the ASP+6% methodology and CMS updates the rate every quarter. Report the NDC alongside J1675, and pair the code with a supporting ICD-10 diagnosis.

Practice management software like Pabau lets oncology and urology practices attach the J-code, the NDC, and the diagnosis to one claim.

HCPCS code J1675 is the Level II J-code for an injection of histrelin acetate at 10 micrograms. One unit equals 10 micrograms, so a 50 mcg dose is billed as 5 units. The code applies to the aqueous injection form given by a provider, not to the implantable pellets sold as Vantas or Supprelin LA.

Medicare Part B pays for J1675 under the ASP+6% methodology, and the rate changes every quarter. This guide covers the code description, the reimbursement rules, and the ICD-10 pairings that establish medical necessity. It also covers NDC reporting and the self-administered drug exclusion that decides whether Part B pays at all.

What is histrelin acetate and what is it used for?

Histrelin acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist used to treat advanced prostate cancer and central precocious puberty. Continuous exposure to a GnRH agonist suppresses pituitary LH and FSH secretion, which in turn reduces sex hormone production. That hormonal suppression is what makes histrelin useful in two very different clinical settings.

• Advanced prostate cancer: Androgen deprivation therapy (ADT) is a standard part of treatment for hormone-sensitive advanced prostate cancer. Histrelin suppresses testosterone to castrate levels, which slows tumor progression. Practices billing this indication use C61 as the supporting diagnosis.
• Central precocious puberty (CPP): CPP is defined as puberty onset before age 8 in girls or 9 in boys. GnRH agonist therapy suppresses early hormonal activation and slows premature bone maturation. The primary ICD-10 code supporting CPP claims is E30.1.
• FDA-approved indications only: Document only the two FDA-approved indications above. Off-label use needs separate medical necessity documentation and may face payer scrutiny.

The brand names Vantas and Supprelin LA refer to implantable subcutaneous pellet formulations of histrelin, not the injection form. The injection coded under J1675 is the aqueous formulation.

Coders who see a Vantas or Supprelin LA chart note should confirm the route and formulation before applying J1675. Implant placement maps instead to a procedure code for surgical implantation.

Medicare reimbursement for HCPCS code J1675

Medicare Part B covers J1675 when a physician or qualified non-physician practitioner administers the injection directly. Coverage does not extend to self-administered forms. Payment follows the Average Sales Price (ASP) methodology that CMS uses for Part B drugs. The allowed amount is ASP plus 6% of the ASP value.

Because ASP rates change every quarter, any dollar figure you have on file may already be out of date. Always pull the current rate from the CMS quarterly ASP pricing file before you calculate expected reimbursement. Reconciling remittances against expected ASP amounts is easier when a system imports electronic remittance advice automatically.

J1675 billing guidelines and coding instructions

Most J1675 claim errors fall into one of four categories: Wrong unit count, missing NDC, absent administration code, or an unsupported diagnosis pairing. Fixing all four before submission is the fastest path to a paid claim. The visual below sets out each field, the entry it takes, and the rejection it prevents.

Dosage units and administration codes

J1675 is billed in units of 10 micrograms, so a dose of 50 mcg requires 5 units. Report the administration separately using the appropriate injection administration CPT code, typically 96372 for a therapeutic subcutaneous or intramuscular injection.

In the office setting Medicare pays the drug line and the administration line independently, so neither one absorbs the other. Both belong on the same claim, each with its own charge.

Place of service and modifiers

• POS 11 (office): The most common setting for histrelin injections in oncology and endocrinology practices.
• POS 22 (outpatient hospital): Drug billed separately under hospital outpatient APC rules.
• Modifier JW: Use when a portion of the drug is discarded, as with a single-dose vial holding unused drug. CMS requires JW for drug wastage reporting on Medicare claims.
• Modifier GY: Used when billing a non-covered service. It is required if a patient requests a service Medicare categorically excludes.

Prior authorization requirements

Traditional Medicare Part B does not run a prior authorization program for J-code drugs. Medicare Advantage plans, commercial insurers, and state Medicaid programs often do. Several publish J1675 on their drug prior authorization lists, so a claim submitted without an approval number is denied on receipt. Check the plan’s current list before the injection is given, not after.

Supported ICD-10 diagnosis codes for J1675

Every J1675 claim needs a supporting ICD-10 diagnosis that establishes medical necessity. The table below lists the most commonly paired codes, and our full ICD-10 code reference covers each one in more depth.

Payers may accept related codes depending on the local coverage determination (LCD) from your Medicare Administrative Contractor. Always verify with the applicable MAC LCD before you bill a diagnosis not shown here.

Document the specific diagnosis clearly in the medical record. A claim pairing J1675 with a diagnosis that does not reflect the patient’s condition is a compliance risk. Link the procedure, the drug code, and the diagnosis on the charge sheet before the claim is generated. That step removes most of this error category.

Is J1675 on the Medicare self-administered drug exclusion list?

No. The physician-administered injection form is not excluded, so Part B covers J1675 when a provider gives the injection. CMS Article A53066 documents the self-administered drug exclusion list, and that exclusion targets formulations a patient takes at home.

The distinction is route of administration. When a physician or qualified practitioner injects histrelin acetate in a clinical setting, the drug is not being self-administered, and Part B coverage applies. The exclusion covers oral or self-injectable formulations a patient would take at home without a provider present.

• Physician-administered injection (office or outpatient): Medicare Part B covered; J1675 applies.
• Self-administered formulation (patient at home): Medicare Part B excluded; may be covered under Medicare Part D.
• Implant placement (Vantas or Supprelin LA): Procedure-code billing applies; J1675 does not describe implant insertion.

Route-of-administration documentation is what protects the practice at post-payment audit. The note must state that a provider administered the injection in the office. Wording that suggests the drug went home with the patient undercuts the claim.

NDC to J1675 crosswalk

CMS requires that National Drug Code (NDC) numbers be reported on Medicare Part B drug claims. The NDC identifies the product, manufacturer, and package size dispensed, which gives the claim traceability back to the dispensed unit.

Omitting the NDC or reporting an incorrect one is a leading cause of Part B drug claim rejections. Practices holding first-pass acceptance above 95% treat NDC reporting as a fixed step in the pre-billing checklist.

Histrelin acetate is available in a limited number of commercially marketed formulations. The table below is a reference crosswalk. NDC numbers change when manufacturers update packaging or discontinue products, so verify the current NDC against the product vial before each claim.

Confirm the specific NDC from the product vial received from your pharmacy or distributor. Manufacturers occasionally reassign NDC numbers, and billing a superseded NDC triggers a rejection even when the drug and the HCPCS code are correct.

J1675 ASP pricing and fee schedule reference

CMS updates ASP-based reimbursement rates for all Part B drugs quarterly, so the rate in effect for Q1 differs from Q3. Publishing a specific dollar figure here would be out of date by the time most readers see it. Pull the rate directly from CMS instead.

• Where to find current ASP rates: CMS publishes quarterly ASP pricing files on its website. Search for “CMS ASP drug pricing” to find the current quarter’s file. It is a downloadable spreadsheet listing all Part B drug codes and their allowed amounts.
• How the rate is calculated: CMS surveys manufacturers for sales data and computes ASP quarterly. The allowed amount for J1675 is ASP plus 6% of that ASP value. Medicare pays 80% of the allowed amount and the patient owes 20% coinsurance.
• Effective date matters: The ASP rate applied to a claim is the rate in effect on the date of service, not the date of billing. A late claim submitted in a new quarter still uses the quarter-of-service rate.

A quarterly check of the ASP pricing file, reconciled against remittances, shows where payment diverged from the expected amount. Check the AAPC HCPCS code reference at the same time to confirm J1675 remains active and unchanged for the billing year.

Related HCPCS J-codes

Coders working with GnRH agonist and hormone therapy injections regularly meet adjacent J-codes. Knowing the distinctions prevents picking the wrong code when several drugs appear on the same encounter. Reworking a wrong-code submission takes far longer than getting the code right at entry.

How Pabau supports HCPCS billing for drug injections

Drug injection claims carry more data points than a typical office visit claim. The J-code, the NDC, the dosage units, the administration code, and the diagnosis all have to agree. A single missing field is enough to generate a rejection.

Practice management software like Pabau keeps those fields together. Pabau’s claims tools for billers let oncology and urology practices build a procedure template carrying the J-code, the NDC, and the diagnosis together. The biller then fills one form instead of five fields across five screens.

A dispensing record linked to the billing record creates a traceable path from the drug received to the claim submitted. For practices running high volumes of ADT injections, that audit trail is worth having when a payer requests records. You can book a demo to see how Pabau handles J-code workflows in urology and oncology practices.

Simplify J-code billing for drug injections

Pabau’s claims management tools help oncology and urology practices attach J-codes, NDC numbers, and ICD-10 diagnoses to claims in one workflow. That reduces manual errors and speeds up reimbursement.

Book a demo

Conclusion

J1675 rewards a routine more than it rewards expertise. Five entries have to agree on each claim, and the rate underneath them moves every quarter. Practices that lose money on this code usually lose it to a stale ASP figure, or an NDC that was never checked against the vial.

So build the check into the calendar, not into someone’s memory. Pull the ASP file at the start of every quarter. Read the NDC off the vial at the point of administration. Confirm the MAC’s coverage article before you bill a new indication.

Every item on that list is data entry, not clinical judgment. That makes it the part of the revenue cycle software can carry for you. Book a demo to see how Pabau keeps the J-code, the NDC, and the diagnosis on one claim line for oncology and urology practices.

Continue your research

Need to understand how denial codes affect J-code reimbursement? Denial codes in medical billing covers the most common remittance adjustment reason codes and how to respond to each.

Want a reference for how drug claims move through the revenue cycle? What is revenue cycle management explains each stage from charge capture through payment posting.

Looking to improve first-pass clean claim rates? Clean claim submission details the checklist every billing team should use before transmitting drug injection claims.

Frequently asked questions